Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Rena

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Diabetology International|September 23, 2016
Salicylic acid: old and new implications for the treatment of type 2 diabetes?Graham Rena, Kei Sakamoto
Circulation|January 31, 2018
Repurposing Metformin for Cardiovascular DiseaseGraham Rena, Chim C Lang
Cellular Signalling|September 5, 2006
Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulinSiobhan Anton, Laura Melville, Graham Rena
Frontiers in Endocrinology|December 24, 2019
Editorial: Metformin: Beyond DiabetesFrédéric Bost, Graham Rena, Benoit Viollet
Digital Health|October 13, 2022
Factors affecting resting heart rate in free-living healthy humansJason Alexander, Magdalena Sovakova, Graham Rena
Diabetologia|July 10, 2013
Molecular mechanism of action of metformin: old or new insights?Graham Rena, Ewan R Pearson, Kei Sakamoto
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
EMBO Reports|January 8, 2004
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1aGraham Rena, Jenny Bain, Matthew Elliott, et al.
Diabetologia|August 5, 2017
The mechanisms of action of metforminGraham Rena, D Grahame Hardie, Ewan R Pearson
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Diabetology International|September 23, 2016
Salicylic acid: old and new implications for the treatment of type 2 diabetes?Graham Rena, Kei Sakamoto
Circulation|January 31, 2018
Repurposing Metformin for Cardiovascular DiseaseGraham Rena, Chim C Lang
Cellular Signalling|September 5, 2006
Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulinSiobhan Anton, Laura Melville, Graham Rena
Frontiers in Endocrinology|December 24, 2019
Editorial: Metformin: Beyond DiabetesFrédéric Bost, Graham Rena, Benoit Viollet
Digital Health|October 13, 2022
Factors affecting resting heart rate in free-living healthy humansJason Alexander, Magdalena Sovakova, Graham Rena
Diabetologia|July 10, 2013
Molecular mechanism of action of metformin: old or new insights?Graham Rena, Ewan R Pearson, Kei Sakamoto
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
EMBO Reports|January 8, 2004
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1aGraham Rena, Jenny Bain, Matthew Elliott, et al.
Diabetologia|August 5, 2017
The mechanisms of action of metforminGraham Rena, D Grahame Hardie, Ewan R Pearson
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Pageof 4